- Home
- SGLY vs APM Comparison
SGLY vs APM Comparison
Compare SGLY & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | APM |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 10.7M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SGLY | APM |
|---|---|---|
| Price | $0.45 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.5K | ★ 52.6K |
| Earning Date | 11-14-2025 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,619,679.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.69 |
| 52 Week High | $5.49 | $7.49 |
Technical Indicators
Market Signals| Indicator | SGLY | APM |
|---|---|---|
| Relative Strength Index (RSI) | 28.29 | 40.14 |
| Support Level | $0.45 | $1.08 |
| Resistance Level | $0.60 | $1.23 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.74 | 26.93 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.